← All trials
NCT05697471
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jan 26, 2023
- Last posted
- Mar 29, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Far Eastern Memorial HospitalLead sponsor
- Far Eastern Memorial HospitalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.